IPP Bureau

Merck to showcase 100+ oncology studies at 2026 ASCO meeting
Merck to showcase 100+ oncology studies at 2026 ASCO meeting

By IPP Bureau - May 14, 2026

Highlighting KEYTRUDA & expanding cancer pipeline

Wegovy delivers consistent weight loss & heart benefits for women across menopause: Novo Nordisk study
Wegovy delivers consistent weight loss & heart benefits for women across menopause: Novo Nordisk study

By IPP Bureau - May 14, 2026

Nearly one in five women worldwide are now living with obesity

Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook
Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook

By IPP Bureau - May 14, 2026

Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros

Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push
Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push

By IPP Bureau - May 14, 2026

Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support

Edwards Lifesciences highlights 10-year data reinforcing durability of RESILIA tissue
Edwards Lifesciences highlights 10-year data reinforcing durability of RESILIA tissue

By IPP Bureau - May 14, 2026

Neuland Laboratories posts blockbuster FY26 performance
Neuland Laboratories posts blockbuster FY26 performance

By IPP Bureau - May 14, 2026

Roche wins CE mark for Alzheimer’s blood test that could transform early diagnosis
Roche wins CE mark for Alzheimer’s blood test that could transform early diagnosis

By IPP Bureau - May 13, 2026

The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline

Breakthrough wearable heart failure therapy enables earlier hospital discharge: UK trial
Breakthrough wearable heart failure therapy enables earlier hospital discharge: UK trial

By IPP Bureau - May 13, 2026

Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care

Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy
Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy

By IPP Bureau - May 13, 2026

The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process

Gilead posts solid Q1 2026 growth & raises full-year outlook on HIV momentum
Gilead posts solid Q1 2026 growth & raises full-year outlook on HIV momentum

By IPP Bureau - May 13, 2026

Industry-academia partnership expands access to advanced life sciences analytics for Indian researchers
Industry-academia partnership expands access to advanced life sciences analytics for Indian researchers

By IPP Bureau - May 13, 2026

High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration

Mankind’s Rajeev Juneja contributes Rs. 9.17 crore to National Defence Fund
Mankind’s Rajeev Juneja contributes Rs. 9.17 crore to National Defence Fund

By IPP Bureau - May 13, 2026

This marks the second consecutive year that Juneja has made a personal contribution towards supporting the armed forces

Vyome secures exclusive license from Impetis for selective JAK inhibitor programs
Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

By IPP Bureau - May 13, 2026

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments

AstraZeneca launches K+ Connect initiative to strengthen hyperkalemia management
AstraZeneca launches K+ Connect initiative to strengthen hyperkalemia management

By IPP Bureau - May 13, 2026

Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure

Brinton Pharma appoints Sathya Narayanan as CEO – India Cluster & JPAC
Brinton Pharma appoints Sathya Narayanan as CEO – India Cluster & JPAC

By IPP Bureau - May 13, 2026

Industry veteran to lead Brinton’s expansion across India and key Asia Pacific markets

Latest Stories

Interviews

Packaging